Headlands Technologies LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Headlands Technologies LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,440 shares of the company’s stock, valued at approximately $186,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. grew its holdings in CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares in the last quarter. SFE Investment Counsel boosted its holdings in shares of CRISPR Therapeutics by 3.6% in the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after buying an additional 203 shares in the last quarter. Orion Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 44.0% in the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares in the last quarter. National Bank of Canada FI boosted its holdings in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after buying an additional 220 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CRSP. Rodman & Renshaw began coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Needham & Company LLC lowered their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Truist Financial lowered their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Finally, Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $75.63.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $48.94 on Friday. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of -17.99 and a beta of 1.68. The company has a 50 day moving average price of $51.12 and a 200-day moving average price of $58.43. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $12.31 million. CRISPR Therapeutics’s quarterly revenue was down 99.3% on a year-over-year basis. During the same period last year, the business posted ($0.98) earnings per share. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.